Request Trial
31 August 2017Big Pharma

Video interview: Predicting Brexit’s life sciences impact

The practical implications of Brexit, including on the Unified Patent Court (UPC), were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
INTA: ‘New normal’ for in-house counsel as budgets fall
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.
Big Pharma
The curtain closes on three major drug disputes
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

More features

INTA: ‘New normal’ for in-house counsel as budgets fall
Mylan withdraws defence claims against Novo in Wegovy dispute
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Astellas blocks generic version of key urology drug until 2030
Orrick adds specialist licensing partner in Silicon Valley
GSK inks licensing deal for liver disease drug
Arnold & Porter adds tech litigator in San Francisco
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs